With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs.It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound.That's one of the key ...